Quantcast

Latest Beta cell Stories

2010-05-13 08:56:00

PHILADELPHIA, May 13 /PRNewswire/ -- By 2020, new cases of Type 1 diabetes in children younger than five are expected to double if current trends continue, according to a study published in The Lancet. Diabetes is an epidemic, with numbers of those suffering from diabetes and its complications increasing worldwide. The International Diabetes Foundation estimates there are 246 million adults worldwide suffering from diabetes today; by 2025, the figure is expected to reach 380 million....

2010-05-10 08:32:00

WELLINGTON, Fla., May 10 /PRNewswire-USNewswire/ -- Dr. Richard Hays announced today that he is now recruiting children with newly diagnosed type 1 diabetes for Protege Encore, a randomized, placebo-controlled Phase III clinical trial. This is the second of two Phase III studies testing the safety and efficacy of an investigational drug called teplizumab. The first study, known as Protege, has completed enrollment of more than 530 subjects with type 1 diabetes. There is currently no...

2010-05-10 09:47:44

In the first study of its type, Australian researchers have shown that healthy people with a genetic predisposition to Type 2 diabetes gain more weight overeating over the short term than their non-genetically-prone counterparts. In a 28-day study undertaken at Sydney's Garvan Institute of Medical Research, scientists set out to mimic the kind of overfeeding that typically takes place during feasting periods like Christmas. Seventeen (otherwise healthy) people with a family history of Type 2...

2010-05-05 20:18:00

SAN DIEGO, May 5 /PRNewswire/ -- ViaCyte, Inc., a preclinical stage stem cell engineering company focused on diabetes, announced today that it has received three additional U.S. Patents: On April 13, the Company was granted U.S. Patent 7,695,963, entitled "Methods for Increasing Definitive Endoderm Production". Methods described in this patent can improve the yield in manufacturing of definitive endoderm and also cells derived from it. On April 13, the Company was also granted U.S....

2010-05-05 20:13:00

SAN DIEGO, May 5 /PRNewswire/ -- Novocell, Inc., a preclinical stage stem cell engineering company focused on diabetes, announced today the Company's shareholders and Board of Directors approved a name change to ViaCyte, Inc. The name ViaCyte retains the Company's identity as a leading cell therapy company, as "-cyte" is derived from the Greek "kytos," which means cell. As the Company is moving towards the market, clear and unambiguous brand recognition is increasingly important. With...

2010-04-15 07:41:18

Mass. General, Boston University researchers run first clinical trial of system using 2 hormones An artificial pancreas system that closely mimics the body's blood sugar control mechanism was able to maintain near-normal glucose levels without causing hypoglycemia in a small group of patients. The system, combining a blood glucose monitor and insulin pump technology with software that directs administration of insulin and the blood-sugar-raising hormone glucagon, was developed at Boston...

2010-04-05 07:45:07

Alpha cells in the pancreas, which do not produce insulin, can convert into insulin-producing beta cells, advancing the prospect of regenerating beta cells as a cure for type 1 diabetes. The findings come from a study at the University of Geneva, co-funded by the Juvenile Diabetes Research Foundation, that is published today in the online edition of the scientific journal Nature. The researchers, led by Dr. Pedro L. Herrera, demonstrated that beta cells will spontaneously regenerate after...

2010-03-22 07:00:00

Program Focuses on Beta Cell Replication and Regeneration NEW YORK, March 22 /PRNewswire-USNewswire/ -- The Juvenile Diabetes Research Foundation, a leader in setting the agenda for diabetes research worldwide, said today that it will begin a diabetes research collaboration with Pfizer, Hadassah Medical Organization, and The Hebrew University of Jerusalem on drugs to replicate and regenerate insulin-producing cells in people with type 1 diabetes. The program, under the direction of...

2010-03-16 06:55:00

CAMBRIDGE, Mass., March 16 /PRNewswire/ -- Tolerx, Inc., today announced the publication in Diabetologia, the journal of the European Association for the Study of Diabetes, of the four-year follow-up clinical data from new onset type 1 diabetes (T1DM) patients (age 12-39) who received a single short course of therapy with otelixizumab (ChAglyCD3). In this clinical study conducted by the Juvenile Diabetes Research Foundation (JDRF) Center for Beta Cell Therapy in Diabetes based in...

2010-03-09 08:20:31

We have known for several years that Hepatitis C, a common cause of liver cirrhosis and cancer, also makes people three to four times more likely to develop Type 2 diabetes. In studying the insulin resistance of 29 people with Hepatitis C, Australian researchers have confirmed that they have high insulin resistance, a precursor to diabetes. However, almost all insulin resistance occurs in muscle, with little or none in the liver, a very surprising finding given that Hepatitis C is a liver...


Latest Beta cell Reference Libraries

0_0d961f30bdfa64859d9b869b063ddcd2
2010-12-03 18:12:26

Insulin, a hormone, is used to regulate carbohydrate and fat metabolism in the body. Insulin causes cells to take up glucose from the blood and store it as glycogen in the liver and muscle. This hormone stops the body from using fat as an energy source by inhibiting the release of glucagons. Without insulin the body fails to take glucose into the bodies cells and in turns uses fat as an energy source. It also has several other anabolic effects throughout the body. Diabetes mellitus results...

More Articles (1 articles) »
Word of the Day
cenobite
  • One of a religious order living in a convent or in community; a monk: opposed to anchoret or hermit (one who lives in solitude).
  • A social bee.
This word comes from the Latin 'coenobium,' convent, which comes from the Greek 'koinobios,' living in community.
Related